The B-Raf mutation has been of a potential therapeutic relevance in melanoma and other cancersin the cancer research community. After the primary set back with the results achieved in clinical trials with the first generation RAF proto-oncogene serine/threonine-protein kinase (RAF kinase) inhibitor, Sorafenib, the validation of B-Raf as a therapeutic target kinase inhibitors is very promising. Discovery Studio 4.0 provides a set of protocols for predicting and analyzing the interaction between protein and ligands. Docking experiments were carried out for compounds identified from Strychnos potatorum seed extract with B-Rafkinase (3C4C) using Accelry’s Discovery Studio 4.0. Out of the five compounds that were selected from Strychnos potatorum seed, four compounds docked with B-Raf kinase,of which, NSC606748 and Strychnine that showed best interactions with 3C4C can be considered as lead compounds for cancer therapeutics.
